Momentum in the Continuous Glucose Monitoring market continues to accelerate with recent estimates valuing CGM device sales of $4+ Billion per year (4). This volume has outpaced the annual revenues of conventional “fingerstick” monitoring and will likely continue outperforming the long-standing technology for many years to come.
Supporting the economic accomplishment is a wealth of clinical literature that demonstrates advanced diabetes technology providing superior health outcomes when compared to traditional care (5).
Like other modalities of care today, millions of people with various chronic conditions are enjoying life with the use of implantable medical technologies, and the robust U.S. implantable device market is expected to grow to $124 billion by 2024. (6)
Because the GlySens System is designed to enable long term continuous monitoring with nothing worn on the skin, and with only minimal need for device interaction, it is expected that it will offer people living with diabetes a new level of empowerment to take better care of their health.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.